@article{Adèle de Masson_Marie Beylot-Barry_Jean-David Bouaziz_Régis Peffault de Latour_François Aubin_Sylvain Garciaz_Michel d’Incan_Olivier Dereure_Stéphane Dalle_Anne Dompmartin_Felipe Suarez_Maxime Battistella_Marie-Dominique Vignon-Pennamen_Jacqueline Rivet_Henri Adamski_Pauline Brice_Sylvie François_Séverine Lissandre_Pascal Turlure_Ewa Wierzbicka-Hainaut_Eolia Brissot_Rémy Dulery_Sophie Servais_Aurélie Ravinet_Reza Tabrizi_Saskia Ingen-Housz-Oro_Pascal Joly_Gérard Socié_Martine Bagot_French Study Group on Cutaneous Lymphomas and Société Française de Greffe de Moëlle et Thérapie Cellulaire_2014, place={Pavia, Italy}, title={Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas}, volume={99}, url={https://haematologica.org/article/view/6970}, DOI={10.3324/haematol.2013.098145}, abstractNote={The treatment of advanced stage primary cutaneous T-cell lymphomas remains challenging. In particular, large-cell transformation of mycosis fungoides is associated with a median overall survival of two years for all stages taken together. Little is known regarding allogeneic hematopoietic stem cell transplantation in this context. We performed a multicenter retrospective analysis of 37 cases of advanced stage primary cutaneous T-cell lymphomas treated with allogeneic stem cell transplantation, including 20 (54%) transformed mycosis fungoides. Twenty-four patients (65%) had stage IV disease (for mycosis fungoides and Sézary syndrome) or disseminated nodal or visceral involvement (for non-epidermotropic primary cutaneous T-cell lymphomas). After a median follow up of 29 months, 19 patients experienced a relapse, leading to a 2-year cumulative incidence of relapse of 56% (95%CI: 0.38–0.74). Estimated 2-year overall survival was 57% (95%CI: 0.41–0.77) and progression-free survival 31% (95%CI: 0.19–0.53). Six of 19 patients with a post-transplant relapse achieved a subsequent complete remission after salvage therapy, with a median duration of 41 months. A weak residual tumor burden before transplantation was associated with increased progression-free survival (HR=0.3, 95%CI: 0.1–0.8; <em>P</em>=0.01). The use of antithymocyte globulin significantly reduced progression-free survival (HR=2.9, 95%CI: 1.3–6.2; <em>P</em>=0.01) but also transplant-related mortality (HR=10<sup>−7</sup>, 95%CI: 4.10<sup>−8</sup>−2.10<sup>−7</sup>; <em>P</em><0.001) in univariate analysis. In multivariate analysis, the use of antithymocyte globulin was the only factor significantly associated with decreased progression-free survival (<em>P</em&gt;=0.04). Allogeneic stem cell transplantation should be considered in advanced stage primary cutaneous T-cell lymphomas, including transformed mycosis fungoides.}, number={3}, journal={Haematologica}, author={Adèle de Masson and Marie Beylot-Barry and Jean-David Bouaziz and Régis Peffault de Latour and François Aubin and Sylvain Garciaz and Michel d’Incan and Olivier Dereure and Stéphane Dalle and Anne Dompmartin and Felipe Suarez and Maxime Battistella and Marie-Dominique Vignon-Pennamen and Jacqueline Rivet and Henri Adamski and Pauline Brice and Sylvie François and Séverine Lissandre and Pascal Turlure and Ewa Wierzbicka-Hainaut and Eolia Brissot and Rémy Dulery and Sophie Servais and Aurélie Ravinet and Reza Tabrizi and Saskia Ingen-Housz-Oro and Pascal Joly and Gérard Socié and Martine Bagot and French Study Group on Cutaneous Lymphomas and Société Française de Greffe de Moëlle et Thérapie Cellulaire}, year={2014}, month={Mar.}, pages={527-534} }